Key takeaways
- Match the ingredient to the written asthma plan. Salbutamol is a short-acting reliever and does not treat airway inflammation alone. Corticosteroid-formoterol combinations can provide anti-inflammatory relief; their prescribed role cannot be read from casing colour. GINA 2025
- Increasing blue-inhaler use needs review. MHRA’s April 2025 reminder cites 47 of 54 children who died from asthma having received at least 3 short-acting reliever inhalers in the previous year. Its advice is to continue the prescribed preventer and seek review when the blue inhaler is needed more than twice a week. MHRA
- MART uses the same eligible combination for maintenance and relief. GINA names budesonide-formoterol and beclometasone-formoterol. Corticosteroid/salmeterol combinations are unsuitable as relievers because salmeterol acts more slowly. GINA 2025
Reliever versus preventer inhalers: the role matters more than the colour
Relievers ease symptoms quickly; preventers deliver anti-inflammatory treatment to reduce future symptoms and attacks. GINA’s evidence for as-needed corticosteroid-formoterol includes four randomised trials involving almost 10,000 adults and adolescents with mild asthma. The meta-analysis it cites found a 55% lower risk of severe attacks requiring oral corticosteroids and a 65% lower risk of emergency visits or hospitalisation compared with a short-acting reliever alone. These study-population results support the prescribed plan; they do not determine a substitute for an individual’s inhaler.
What does a reliever inhaler do?
A reliever provides quick relief from wheeze, chest tightness, cough or breathlessness according to the asthma plan. Traditional relievers include short-acting beta2 agonists such as salbutamol, which relax airway muscle. Their effect on tightening does not replace anti-inflammatory treatment for asthma.
The 2025 Global Initiative for Asthma strategy describes three reliever categories: a short-acting beta2 agonist alone, a corticosteroid with formoterol, and a corticosteroid with a short-acting beta2 agonist. The latter two add anti-inflammatory treatment whenever the prescribed reliever is used. The written plan identifies the exact combination and its role.
What does a preventer inhaler do?
A preventer controls airway inflammation and reduces future symptoms and attacks when used as prescribed. It is also called controller or maintenance treatment. Many contain an inhaled corticosteroid such as budesonide, beclometasone or fluticasone. Some combine a corticosteroid with a long-acting bronchodilator.
In its 24 April 2025 reminder, MHRA cites 87%, or 47 of 54 children who died from asthma, having received 3 or more short-acting reliever inhalers during the preceding year. This association supports reviewing increasing use, which can mask deterioration. The reminder asks patients to continue their prescribed preventer when asthma feels controlled and seek review when a blue inhaler is needed more than twice a week. A preventer may produce no immediate sensation; its benefit can be less noticeable than quick relief.
Can one inhaler be both reliever and preventer?
Yes, when the prescribed ingredient combination and regimen support both roles. In anti-inflammatory reliever (AIR) treatment, an eligible combination is used for symptom relief. In maintenance-and-reliever therapy (MART), the same eligible inhaler has a regular maintenance role and an as-needed reliever role.
| Prescribed role | General purpose | Important limitation |
|---|---|---|
| Short-acting reliever | Rapid symptom relief | Does not supply maintenance anti-inflammatory treatment by itself |
| Separate preventer | Ongoing anti-inflammatory control | Is not automatically the inhaler for an acute attack |
| AIR | Anti-inflammatory medicine with each symptom-relief use | Only specified ingredient/device combinations are suitable |
| MART | One eligible combination used for maintenance and relief | Must follow the individual’s prescribed plan and maximum-use instructions |
Formoterol acts rapidly despite being a long-acting bronchodilator. In MART it is paired with a corticosteroid, commonly budesonide or beclometasone. GINA also uses the name SMART for this maintenance-and-reliever regimen.
GINA excludes corticosteroid combinations with non-formoterol bronchodilators from reliever use. Salmeterol has a slower onset; repeated relief use of combinations containing vilanterol or indacaterol lacks the necessary safety or efficacy evidence. A different long-acting ingredient therefore cannot be assigned the same role. Using the wrong device during worsening symptoms can delay effective treatment.
Why is inhaler colour an unsafe shortcut?
Colour does not identify ingredients or the prescribed role. Colours vary by brand, manufacturer, device and market. Purple, red, pink or grey devices may contain combination treatment, but colour does not state whether the device is prescribed as maintenance only or as maintenance and reliever. Forum questions often show people trying to identify an unfamiliar inhaler from “blue”, “brown” or “pink” alone. That signal is useful: the label needs to answer what colour cannot.
Read the active ingredients, strength, device name and pharmacy label, and match them to the written asthma action plan. GINA reports incorrect inhaler technique in up to 70 to 80% of patients; people may be unaware of the problem.
For a metered-dose inhaler, HealthHub’s instructions describe slow, steady inhalation coordinated with pressing the canister. They specify holding the breath for about 10 seconds, or as long as possible. Releasing the mist too early or late, opening the mouth when it hits the throat, and not inhaling or holding the breath long enough can reduce delivery. A spacer can help with these problems. Dry-powder and breath-actuated devices require different actions, so demonstrate the actual inhaler to a clinician or pharmacist.
What changes the answer?
Diagnosis, age, the ingredient combination and device technique determine how the inhaler is used.
- The diagnosis. Asthma and chronic obstructive pulmonary disease can use some of the same ingredients in different treatment plans.
- Age and device ability. Young children and people who cannot coordinate a device may need a spacer, mask or different inhaler type.
- The exact ingredients. Only certain corticosteroid/rapid-bronchodilator combinations have an AIR or MART role.
- Pregnancy and other conditions. Asthma control remains important, but medicine decisions require individual review.
- Symptom pattern and recent use. Night waking, activity limitation, repeated reliever use or attacks can signal inadequate control or poor technique.
- Technique and adherence. A suitable medicine may deliver little to the lungs if the device is used incorrectly.
When is breathing trouble urgent?
Follow the emergency steps in the person’s asthma action plan and seek urgent help for severe or worsening breathing trouble. Seek urgent medical help if breathing is rapidly worsening, the prescribed reliever is not helping as expected, speaking or walking is difficult because of breathlessness, the person is becoming exhausted or drowsy, or the lips or face look blue or grey. Do not wait for an inhaler to run out before asking for help when symptoms remain severe.
Increasing reliever use, night waking or uncertainty about which device to use calls for an asthma review. Bring every inhaler and spacer and show how you use them. GINA’s device checklist calls for watching a demonstration, identifying the exact error and checking again after correction. The demonstration may need repeating 2 to 3 times during the appointment; errors can recur within 4 to 6 weeks after training.
Ask for the written plan to identify each device’s ingredients and role. Do not borrow someone else’s inhaler or reassign a maintenance product as a reliever from its colour or online advice.
Do and don’t
Do:
- Bring every inhaler and spacer to the review and demonstrate how you use them.
- Keep the written plan current when the prescribed product or role changes.
- Check the dose counter, or track use if the device has none, so a replacement is ready before it runs out.
Don’t:
- Borrow an inhaler or treat a corticosteroid/salmeterol device as a MART reliever.
- Bite the MDI mouthpiece or release the mist before the slow inhalation starts.
- Wait for an inhaler to empty when the prescribed reliever is failing to relieve severe symptoms.
Sources
- Global Initiative for Asthma: 2025 GINA Strategy Report, November update. See Box 4-1 for AIR/MART definitions, page 79 for the trial evidence and Box 5-2 on page 110 for device checks.
- UK MHRA: Patients with asthma reminded of the increased risk of severe asthma attacks from overusing blue inhalers.
- Singapore HealthHub: Metered Dose Inhalers.
- Reddit r/Asthma: Confused Used only as a reader-question signal.
